Asia Pacific In Vitro Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Asia Pacific In-Vitro Diagnostics Market is Segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, Immunodiagnostics, Hematology, and Other Test Types), Product (Instruments, Reagents, and Other Products), Usability (Disposable IVD Devices and Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Other Applications), End User (Diagnostic Laboratories, Hospitals and Clinics, and Other End Users), and Geography (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific). The Market Provides the Value (in USD Million) for the Above-Mentioned Segments.

Asia Pacific In Vitro Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Asia Pacific In-Vitro Diagnostics Market Size

View Global Report
Asia Pacific In Vitro Diagnostics Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Market Size (2025) USD 25.59 Billion
Market Size (2030) USD 33.76 Billion
CAGR (2025 - 2030) 5.70 %
Market Concentration Medium

Major Players

Asia Pacific In Vitro Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Asia Pacific In Vitro Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Asia Pacific In-Vitro Diagnostics Market Analysis

The Asia Pacific In Vitro Diagnostics Market size is estimated at USD 25.59 billion in 2025, and is expected to reach USD 33.76 billion by 2030, at a CAGR of 5.7% during the forecast period (2025-2030).

The COVID-19 outbreak affected the Asia-Pacific in-vitro diagnostic market's growth adversely in its preliminary phase. However, this market gained traction due to the significant urge and rapid demand for newly launched emergency-use authorized in-vitro diagnostic tests for COVID-19 detection. For instance, in May 2022, Cipla Limited started the commercialization of the 'RT-Direct' multiplex COVID-19 RT-PCR Test kit in India in partnership with Genes2Me Pvt. Ltd. This kit was validated at an Indian Council of Medical Research (ICMR)-approved center. However, the rapid demand for newly launched emergency-use authorized in-vitro diagnostic tests for COVID-19 detection compensated for this detrimental impact. However, the market is growing at a stable pace due to a resumption of diagnosis procedures, manufacturing activities, and availability of products. It is expected to witness a similar trend over the coming years.

Further, the high cases of chronic diseases, the increasing use of point-of-care (POC) diagnostics, advanced technologies in vitro diagnostic products, and increasing awareness and use of personalized medicine and companion diagnostics are among the major factors driving the growth of the studied market. For instance, the 2021 International Diabetes Federation (IDF) projects that the number of people with diabetes in Southeast Asia will increase by 68%, reaching 152 million by 2045. The same report also reported that the Western Pacific region holds the third-highest prevalence of diabetes (11.9%) globally. The number of diabetic cases is estimated to increase in the Western Pacific region by 27%, reaching 260 million by 2045, and the prevalence of diabetes will increase by 21% in 2045. Such a high incidence of chronic diseases like diabetes in the given region is increasing the demand for diagnostics associated with the diseases.

Additionally, as per the article published in the Chinese Medical Journal in March 2022, China is experiencing a greater cancer incidence. In China, there were about 4.8 million new cancer cases in 2022, with lung cancer being the most prevalent type. Thus, the increasing incidence of cancer cases increased the demand for associated diagnostics, contributing to the market.

The strategies adopted by the market players, such as product launches, partnerships, and collaboration, are expected to propel the market's growth. For instance, in March 2021, OpGen announced that it had received regulatory approval from the Chinese National Medical Products Administration for its Curetis Unyvero System as an in-vitro diagnostics instrument. In April 2021, Otsuka Pharmaceutical Co., Ltd., in collaboration with Denka Company Limited, launched the Helicobacter Pylori test kit, QuickNavi-H. Pylori. It is a diagnostic kit that utilizes immunochromatography to confirm the presence or absence of Helicobacter Pylori antigens in a stool sample. The test kit will be used in medical institutions as it enables rapid evaluation in eight minutes by adding three drops of the sample liquid to the kit. Thus, the market can show significant growth over the forecast period due to these technological advances.

Thus, the reasons mentioned above may drive the market. However, stringent regulations regarding product approvals and cumbersome reimbursement procedures may slow the market's growth.

Asia Pacific In-Vitro Diagnostics Industry Overview

The Asia-Pacific in vitro diagnostics market is highly competitive and includes several major players. Regarding market share, a few major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at lower prices. Some of the major players in the region are BioMérieux SA, Danaher (Beckman Coulter), F Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Abbott Laboratories, Arkray Inc., Sysmex Corporation, Ortho Clinical Diagnostics, Siemens Healthineers, Thermo Fischer Scientific Inc., and Qiagen NV.

Asia Pacific In-Vitro Diagnostics Market Leaders

  1. Abbott

  2. Siemens Healthineers AG

  3. bioMérieux SA

  4. Thermo Fisher Scientific

  5. F Hoffmann-La Roche Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Asia Pacific In Vitro Diagnostics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Asia Pacific In-Vitro Diagnostics Market News

  • February 2023: Mylab Discovery Solutions announced it is all set to roll out new in vitro diagnostic (IVD) medical devices and kits to empower small labs in India.
  • February 2022: Mylab Discovery Solutions launched CoviSwift, a point-of-care (POC) testing solution comprising the CoviSwift assay and Compact-Q machines and process 16 samples within 40 minutes, four times faster than the typical RT-PCR testing procedure.

Asia Pacific In-Vitro Diagnostics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Chronic Diseases
    • 4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
    • 4.2.3 Advanced Technologies in In-vitro Diagnostic Products
    • 4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations Regarding Product Approvals
    • 4.3.2 Cumbersome Reimbursement Procedures
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Test Type
    • 5.1.1 Clinical Chemistry
    • 5.1.2 Molecular Diagnostics
    • 5.1.3 Immuno Diagnostics
    • 5.1.4 Hematology
    • 5.1.5 Other Test Types
  • 5.2 By Product
    • 5.2.1 Instruments
    • 5.2.2 Reagents
    • 5.2.3 Other Products
  • 5.3 By Usability
    • 5.3.1 Disposable IVD Devices
    • 5.3.2 Reusable IVD Devices
  • 5.4 By Application
    • 5.4.1 Infectious Diseases
    • 5.4.2 Diabetes
    • 5.4.3 Cancer/Oncology
    • 5.4.4 Cardiology
    • 5.4.5 Autoimmune Diseases
    • 5.4.6 Nephrology
    • 5.4.7 Other Applications
  • 5.5 By End User
    • 5.5.1 Diagnostic Laboratories
    • 5.5.2 Hospitals and Clinics
    • 5.5.3 Other End Users
  • 5.6 By Geography
    • 5.6.1 China
    • 5.6.2 Japan
    • 5.6.3 India
    • 5.6.4 Australia
    • 5.6.5 South Korea
    • 5.6.6 Rest of Asia-Pacific

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BioMérieux SA
    • 6.1.2 Danaher (Beckman Coulter)
    • 6.1.3 F Hoffmann-La Roche Ltd.
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Bio-Rad Laboratories Inc.
    • 6.1.6 Abbott Laboratories
    • 6.1.7 Arkray Inc.
    • 6.1.8 Sysmex Corporation
    • 6.1.9 Quidel Corporation (Ortho Clinical Diagnostics)
    • 6.1.10 Siemens Healthineers
    • 6.1.11 Thermo Fischer Scientific Inc.
    • 6.1.12 Qiagen NV
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Asia Pacific In-Vitro Diagnostics Industry Segmentation

As per the scope of the report, in vitro diagnostics involve medical devices and consumables that are utilized to perform in-vitro tests on various biological samples. They diagnose various medical conditions, such as diabetes and cancer. The Asia Pacific In-vitro Diagnostics Market is segmented by test type (clinical chemistry, molecular diagnostics, immunodiagnostics, hematology, and other test types), product (instruments, reagents, and other products), usability (disposable IVD devices and reusable IVD devices), application (infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and other applications), end user (diagnostic laboratories, hospitals and clinics, and other end users), and Geography (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific). The report offers values (in USD) for the above segments.

By Test Type Clinical Chemistry
Molecular Diagnostics
Immuno Diagnostics
Hematology
Other Test Types
By Product Instruments
Reagents
Other Products
By Usability Disposable IVD Devices
Reusable IVD Devices
By Application Infectious Diseases
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Diseases
Nephrology
Other Applications
By End User Diagnostic Laboratories
Hospitals and Clinics
Other End Users
By Geography China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Need A Different Region or Segment?
Customize Now

Asia Pacific In-Vitro Diagnostics Market Research FAQs

How big is the Asia Pacific In Vitro Diagnostics Market?

The Asia Pacific In Vitro Diagnostics Market size is expected to reach USD 25.59 billion in 2025 and grow at a CAGR of 5.70% to reach USD 33.76 billion by 2030.

What is the current Asia Pacific In Vitro Diagnostics Market size?

In 2025, the Asia Pacific In Vitro Diagnostics Market size is expected to reach USD 25.59 billion.

Who are the key players in Asia Pacific In Vitro Diagnostics Market?

Abbott, Siemens Healthineers AG, bioMérieux SA, Thermo Fisher Scientific and F Hoffmann-La Roche Ltd are the major companies operating in the Asia Pacific In Vitro Diagnostics Market.

What years does this Asia Pacific In Vitro Diagnostics Market cover, and what was the market size in 2024?

In 2024, the Asia Pacific In Vitro Diagnostics Market size was estimated at USD 24.13 billion. The report covers the Asia Pacific In Vitro Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Asia Pacific In Vitro Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

APAC Infectious Disease Diagnosis & Treatment Industry Report

Statistics for the 2025 Asia Pacific In Vitro Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia Pacific In Vitro Diagnostics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.